alendronate / Generic mfg. - LARVOL DELTA

Gut Microbiota and SCFA Changes After Alendronate-Calcitriol Therapy in Postmenopausal Osteoporosis. (PubMed, Int J Womens Health) - "Alendronate-calcitriol therapy was associated with improved bone metabolism and treatment-associated shifts in gut microbial composition, microbial functional potential, and propionate-related SCFA profiles. These findings provide preliminary evidence for microecological changes accompanying conventional PMO therapy."

Journal • Osteoporosis • Rheumatology • TRAP

Acute Orbital Inflammation following Neridronate Therapy: A Case Report. (PubMed, Case Rep Ophthalmol) - "While most reported cases involve agents such as zoledronate or alendronate, reports associated with neridronate remain exceedingly rare...Following the initiation of high-dose oral prednisone (1 mg/kg/day), the patient exhibited rapid clinical improvement within 48 h and near-complete radiologic resolution by 15 days. This case underscores the importance of recognizing neridronate-associated orbital inflammation as a potential adverse reaction, even following intramuscular injection. Despite its severe presentation, the condition typically demonstrates a rapid and favorable response to systemic corticosteroid therapy."

Journal • Dermatology • Inflammation • Musculoskeletal Pain • Ocular Inflammation • Ophthalmology • Pain • Scleritis • CRP

Suspected Ampalaya-Induced Acute Pancreatitis and Hepatitis in a 70-Year-Old Woman: A Case Report (ACG 2026) - "Although generally regarded as safe, its potential for hepatotoxic or pancreatic injury remains poorly characterized, with only one previously documented case of pancreatitis associated with concurrent pazopanib therapy...Current medications included alendronate 70 mg weekly, apixaban 2.5 mg twice a day, cholecalciferol 2000 unit daily, fish oil 1000 mg daily, levothyroxine 112 mcg daily, magnesium glycinate 240 mg daily, rosuvastatin 5 mg daily...This case suggests a probable association between ampalaya ingestion and acute pancreatitis with concomitant hepatocellular injury. Given the widespread use of Momordica charantia for diabetes management, clinicians should maintain a high index of suspicion for herbal-supplement induced pancreatic and hepatic toxicity when more common etiologies have been excluded."

Case report • Clinical • Diabetes • Gastroenterology • Hepatology • Immunology • Infectious Disease • Inflammation • Metabolic Disorders • Pancreatitis • Type 2 Diabetes Mellitus

Cardiovascular Outcomes with Romosozumab Versus Alendronate in Osteoporosis: A Real-World Propensity-Matched Cohort Study (ACR Convergence 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Cardiovascular • Osteoporosis • Rheumatology

Medication-related osteonecrosis of the external auditory canal and treatment with teriparatide. (PubMed, JCEM Case Rep) - "A 67-year-old woman developed left-sided MROEAC after 15 years of alendronate followed by a short course of denosumab. Teriparatide was well tolerated and was associated with increased bone turnover markers, but radiologic resolution was incomplete. Surgical management may still be necessary."

Journal • Otorhinolaryngology

Potent bisphosphonate therapy for preventing fractures after denosumab discontinuation in osteoporosis: A GRADE-assessed systematic review and meta-analysis. (PubMed, Medicine (Baltimore)) - "Potent BP therapy was related to decreased vertebral fracture risk after denosumab termination, particularly when compared with no subsequent therapy. Evidence versus SERM comparators was limited and inconclusive. The results are in agreement with the present clinical guideline recommendations for sequential BP use after the discontinuation of denosumab, but further high-quality randomized trials are required to prove this."

Clinical • Journal • Retrospective data • Review • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Bisphosphonate therapy for thalassemia-related bone disorders in children and young adults: a systematic review. (PubMed, Ann Pediatr Endocrinol Metab) - "Six studies evaluated pamidronate, 3 zoledronate, and 2 alendronate. Bisphosphonates may improve bone density and alleviate pain in TDT-related bone disease. Larger randomized controlled trials are required to determine long-term efficacy, fracture outcomes, and optimal treatment regimens."

Journal • Endocrine Disorders • Genetic Disorders • Hematological Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Osteoporosis • Pain • Pediatrics • Rheumatology

Cardiovascular Safety Signals of Osteoporosis Therapies: A FAERS Pharmacovigilance Study. (PubMed, Mediterr J Rheumatol) - "We conducted a retrospective pharmacovigilance analysis of FAERS reports between January 2019 and December 2024, identifying all reports involving alendronate, risedronate, zoledronic acid, denosumab, teriparatide, abaloparatide, or romosozumab. Romosozumab and zoledronic acid demonstrated prominent cardiovascular disproportionality signals in FAERS, whereas denosumab, abaloparatide, and teriparatide showed more favorable reporting profiles. These findings should not discourage osteoporosis treatment but underscore the importance of individualised cardiovascular risk assessment and the need for further prospective evaluation to inform safe therapy selection."

Adverse events • Journal • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction • Osteoporosis • Rheumatology

Osteoporosis treatment patterns and bone mineral density response in kidney transplant recipients: A single-center retrospective study (TTS 2026) - "Treatment groups included bisphosphonates (BP; alendronate, n=191), denosumab (n=261), and romosozumab (n=46), with some patients receiving more than one agent. In this cohort of kidney transplant recipients, osteoporosis treatment patterns shifted substantially over the past decade from bisphosphonates toward denosumab and romosozumab. All therapies were associated with improvements in bone mineral density, although the magnitude and anatomical distribution of response differed among agents. These findings reflect recent shifts in clinical practice and support individualized osteoporosis management after kidney transplantation."

Retrospective data • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology • Transplantation

An Injectable Metal-Drug Supramolecular Condensate Enables Radiosensitization and Systemic Antitumor Immunity for Post-Surgical Osteosarcoma Therapy. (PubMed, Adv Sci (Weinh)) - "Here we report an injectable metal-drug supramolecular condensate formed from hafnium ions and alendronate (Hf-ALN) and loaded with the COX-2 inhibitor celecoxib (CXB) for synergistic radioimmunotherapy of postoperative osteosarcoma. This strategy enhances dendritic cell maturation, activates cytotoxic CD8+ T cells, and reduces regulatory T-cell infiltration. In orthotopic osteosarcoma models, CXB@Hf-ALN combined with RT suppresses tumor recurrence, preserves bone integrity, inhibits pulmonary metastasis, and prolongs survival with minimal systemic toxicity, offering a promising strategy to improve postsurgical RT outcomes in osteosarcoma."

Journal • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • CD8

Clinical study of polarized infrared light irradiation of stellate ganglion in the treatment of postmenopausal osteoporosis (ChiCTR) - P=N/A | N=60 | Completed | Sponsor: Foshan hospiital of Traditional Chinese Medicine; Foshan hospiital of Traditional Chinese Medicine

New trial • Back Pain • Lumbar Back Pain • Osteoporosis • Rheumatology

Alendronate alters mineral composition and has potential to restore enthesis strength without preventing trabecular bone loss during unloading of the supraspinatus enthesis. (PubMed, Bone) - "However, combined unloading and turnover suppression reduced post yield properties, highlighting tradeoffs for enthesis quality under low load conditions. These findings show that disuse induced bone loss at the supraspinatus enthesis is driven by formation and that bisphosphonates, while modifying mineral composition, do not prevent structural degeneration."

Journal • Cardiovascular • Osteoporosis

Clinical and Radiological Outcomes of Oral Bisphosphonate Therapy Combined with Conservative Treatment in Subchondral Bone Marrow Edema of the Knee: A Retrospective Cohort Study. (PubMed, J Clin Med) - " Adding oral alendronate to conservative treatment was associated with greater clinical improvement, earlier full weight-bearing, and a more favorable radiological response at three months. Prospective randomized studies are needed to confirm these findings."

Journal • Retrospective data • Immunology • Osteoarthritis • Pain • Rheumatology

Enzyme-Responsive Composite Hydrogel Coating Containing Nano-HA/Nano-ZnO with Pro-Osteogenic and Anti-Osteoclastic Properties. (PubMed, Macromol Biosci) - "Nano-zinc oxide (nano-ZnO), nano-hydroxyapatite (nano-HA), and phosphate-ester-functionalized alendronate (ALNP) are incorporated to confer antibacterial activity, promote osteogenesis, and enable enzyme-responsive release of anti-osteoporosis alendronate (ALN)...The released ALN inhibits the receptor activator of nuclear factor-κB ligand (RANKL)-induced differentiation of RAW264.7 macrophages into osteoclasts. Overall, this surface modification strategy integrates enzyme-responsive ALN release with composite hydrogel coating on PPENK, realizing antibacterial, osteogenic, and anti-osteoclastic effects in vitro."

Journal • Osteoporosis • Rheumatology

Naringin attenuates orchidectomy-induced bone loss in male rats: evidence from bone remodeling and telomere-related indices. (PubMed, J Mol Histol) - "Naringin was also associated with higher TERT expression and longer relative telomere length, whereas alendronate produced comparable structural and turnover responses but weaker telomere-related changes. These findings suggest that naringin attenuates ORX-induced bone loss in male rats, with coordinated changes in skeletal remodeling and telomere-related indices."

Journal • Preclinical • Osteoporosis • Rheumatology • TERT • TNFSF11 • TRAP

Comparison of Naringenin and Alendronate in the Attenuation of Ovariectomy-Induced Osteoporosis by Modulating Autophagy, Apoptosis, and Oxidative Stress in Rats. (PubMed, Iran J Pharm Res) - "Naringenin and AL mitigated OVX-associated osteoporotic changes without restoring systemic estradiol levels, and these effects were accompanied by shifts in apoptosis- and autophagy-related gene expression. These findings suggest that the beneficial effects of AL and NA may be associated with the modulation of oxidative stress and apoptosis- and autophagy-related mechanisms."

IO biomarker • Journal • Preclinical • B Cell Lymphoma • Lymphoma • Oncology • Osteoporosis • Rheumatology • BCL2 • BECN1 • BGLAP • CASP9 • CAT • MAP1LC3B

Tumor-Adhesive Ru/Ca-Tannic Acid Network Enables Phosphate-Independent Calcification and Photothermal-Synergistic Therapy for Osteolytic Bone Metastasis. (PubMed, Small) - "The Ru/Ca-TA-ALN network, assembled from ruthenium ions (Ru3+), calcium ions (Ca2+), tannic acid (TA), and alendronate (ALN), co-integrates Ca2+ and phosphate-bearing moieties within a single coordination framework, allowing autonomous mineral deposition upon adhesion to tumor cell membranes...In a murine breast cancer bone metastasis model, calcification-photothermal synergy significantly reduced tumor burden, mitigated bone destruction, and prolonged survival, while maintaining favorable biocompatibility. By transforming biomineralization into a controllable interfacial therapeutic modality, this work establishes a strategy that couples tumor suppression with bone reconstruction for metastatic bone disease."

Journal • Breast Cancer • Oncology • Solid Tumor

Effects of alendronate on bone turnover and bone mineral density in type 1 diabetes: a randomised controlled trial (EASD 2026) - "Alendronate treatment effectively suppresses bone turnover in individuals with type 1 diabetes. However, despite this, 24 months of treatment did not result in a significant increase in BMD. Pending HR-pQCT data may help elucidate potential effects on bone microarchitecture."

Clinical • Diabetes • Metabolic Disorders • Osteoporosis • Type 1 Diabetes Mellitus

Agonism of amylin and calcitonin receptors via cagrilintide, CagriSema and zenagamtide are beneficial for bone health in a rat model of ovariectomy-induced osteoporosis (EASD 2026) - "Alendronate (10 ug/kg) and sham operated animals served as a positive and healthy controls, respectively...Weight matching by energy restriction reduced bone formation, as reflected by P1NP levels, compared to vehicle and this decrease was ameliorated after treatment with cagrilintide, semaglutide, CagriSema or zenagamtide (p<0.05) suggesting an overall net- beneficial effect on bone turnover... Cagrilintide, CagriSema, and zenagamtide ameliorated bone loss and structural deterioration in OVX rats. This was not observed to a similar extent with the GLP1R agonist semaglutide, thereby, suggesting a uniquely beneficial effects of these AMYR/CTR agonists for bone health. Thus, such amylin agonist may promote a healthier weight loss in patients by mitigating bone loss."

Preclinical • Metabolic Disorders • Obesity • Osteoporosis • COL1A2

US/ROS-responsive ALN-modified polymer nanoparticles enhance the efficacy of infiltration anesthesia through improved bone targeting and permeation. (PubMed, Biomater Sci) - "The nanoparticles, which were surface-modified with alendronate (ALN) via an ROS-cleavable thioketal (TK) linker and coloaded with bupivacaine (BUPI) and perfluorohexane (PFH), enabled enhanced bone targeting and penetration...Biocompatibility was confirmed via histology and serum biomarkers. By overcoming maxillofacial bone barriers and enabling responsive, biphasic drug release, this platform represents a promising strategy to address the limitations of current local anesthetics in dentistry, reducing local anesthesia failure rates and improving perioperative pain control."

Journal • Anesthesia • Pain

Dual-targeting poly(2-oxazoline)-coated porous silicon nanoparticles for improving osteosarcoma therapy. (PubMed, Nanoscale) - "Surface decoration with alendronate (ALN) and/or insulin growth factor-2 receptor antibody (Ab) enhanced bone cancer cell targetability...Importantly, DOX-loaded dual-targeted pSiNPs produced significantly greater cytotoxicity than free DOX, non-targeted, or single-targeted formulations. These findings establish this dual-targeted drug delivery system as potent nanocarrier system for osteosarcoma, combining high payload capacity, controlled release, and selective cancer cell targeting to advance therapeutic outcomes."

Journal • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

In men with osteoporosis/osteopenia, denosumab, alendronate, and zoledronic acid did not differ for lumbar spine BMD at 12 mo. (PubMed, Ann Intern Med) - "GIM/FP/GP: [Formula: see text] Endocrinology: [Formula: see text] Geriatrics: [Formula: see text] Rheumatology: [Formula: see text]."

Journal • Endocrine Disorders • Osteoporosis • Rheumatology

Bone health in advanced prostate cancer: pathophysiology and management strategies. (PubMed, Oncologist) - "Options include bisphosphonates such as zoledronic acid and alendronate, and the receptor activator of nuclear factor kappa-B ligand inhibitor denosumab...Alongside BHAs, there are treatment options for metastatic castration-resistant prostate cancer associated with beneficial bone-related effects, notably abiraterone acetate, enzalutamide, and radium-223...We also present a test-and-treatment algorithm for bone health management in men with metastatic prostate cancer. Improving treatment-related bone loss and proactively managing bone metastases should be standard practice in all men with prostate cancer to improve health outcomes and quality of life."

Journal • Castration-Resistant Prostate Cancer • Endocrine Disorders • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Resolution of Osteoporosis in a Breast Cancer Survivor Following Supervised Osteogenic Loading and High-Adherence Lifestyle Modification: A Case Report. (PubMed, Cureus) - "Treatment had included neoadjuvant chemotherapy, modified radical mastectomy, regional nodal irradiation, one year of trastuzumab, and 10 years of tamoxifen...She declined alendronate and began a structured lifestyle program on Day 0 consisting of weekly supervised osteogenic loading, progressive resistance training, increased aerobic activity, balance and mobility work, a whole-food plant-forward diet, and supplementation...Over approximately 16 months without anti-resorptive medication, this patient's lumbar spine moved from the osteoporotic to the osteopenic range, with concordant improvement at the femoral neck. Causality cannot be attributed to any single component of the intervention, but the case supports further study of structured lifestyle-based bone health strategies in breast cancer survivorship."

Journal • Rheumatology • Women's Health • HER-2

Comparison of the effects of denosumab and alendronate on fracture risk and bone metabolism in postmenopausal rheumatoid arthritis patients treated with oral glucocorticoids: A propensity score-matched retrospective cohort study. (PubMed, Ther Adv Musculoskelet Dis) - "The absolute risk difference for fragility fracture with denosumab versus alendronate was 3.2% (95% CI: -2.2% to 8.6%), but this finding remains inconclusive due to insufficient power and rare events. Larger prospective studies are needed to clarify fracture outcomes."

Journal • Retrospective data • Immunology • Inflammatory Arthritis • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatoid Arthritis • Rheumatology